Corrigendum to “Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms” [Vaccine 68 (2025) 127942]

Vaccine 2026

View at publisher

Authors: Taro Saito, Arnaud Couzinet, Toshihiro Suzuki, Manami Shimomura, Akihide Ryo, Kei Miyakawa, Yuki Katayama, Tetsuya Nakatsura

DOI: 10.1016/j.vaccine.2026.128267

Cited by: 0

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Immune responses and vaccinations COVID-19 Clinical Research Studies